Serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus vandetanib changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review